CORRECTION Open Access

## Correction to: Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries



Moses Badio<sup>1†</sup>, Edouard Lhomme<sup>2†</sup>, Mark Kieh<sup>1</sup>, Abdoul Habib Beavogui<sup>3</sup>, Stephen B. Kennedy<sup>1</sup>, Seydou Doumbia<sup>4</sup>, Bailah Leigh<sup>5</sup>, Samba O. Sow<sup>6</sup>, Alpha Diallo<sup>7</sup>, Daniela Fusco<sup>7</sup>, Matthew Kirchoff<sup>8</sup>, Monique Termote<sup>2</sup>, Renaud Vatrinet<sup>9</sup>, Deborah Wentworth<sup>10</sup>, Helène Esperou<sup>7</sup>, H. Clifford Lane<sup>8</sup>, Jerome Pierson<sup>8</sup>, Deborah Watson-Jones<sup>11</sup>, Céline Roy<sup>2</sup>, Eric D'Ortenzio<sup>9,12</sup>, Brian Greenwood<sup>11</sup>, Genevieve Chêne<sup>2</sup>, Laura Richer<sup>2</sup>, James D. Neaton<sup>10</sup>, Yazdan Yazdanpanah<sup>9,12\*</sup> and the PREVAC study team

Correction to: Trials 22, 86 (2021) https://doi.org/10.1186/s13063-021-05035-9

Following the publication of the original article [1], we were notified of an error in the affiliation of 3 authors of the article: Celine Roy, Laura Richert and Genevieve Chene.

Their affiliation was initially mentioned as: "Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia"

However, their correct affiliation is: Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219, CHU Bordeaux, CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, F-33000, Bordeaux, France.tp

The original article can be found online at https://doi.org/10.1186/s13063-021-05035-9.

Full list of author information is available at the end of the article

## **Author details**

<sup>1</sup>Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia. <sup>2</sup>Univ. Bordeaux, Inserm, Bordeaux Population Health Research, Center, UMR 1219, CHU Bordeaux, CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, F-33000 Bordeaux, France. <sup>3</sup>Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Mafèrinyah, Guinea. <sup>4</sup>University of Sciences, Technique and Technology of Bamako, Bamako, Mali. <sup>5</sup>College of Medicine and Allied Health Sciences (COMAHS), University of Sierra Leone, Freetown, Sierra Leone. <sup>6</sup>Centre pour le Développement des Vaccins, Bamako, Mali. <sup>7</sup>INSERM, Pôle de Recherche Clinique, 75013 Paris, France. <sup>8</sup>National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA. <sup>9</sup>REACTing, Institut Thématique Immunologie, Inflammation, Infectiologie et Microbiologie, Inserm, Paris, France. <sup>10</sup>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA. 11London School of Hygiene & Tropical Medicine, London, UK.  $^{12}\mathrm{AP}\text{-HP}$ , Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales, F-75018 Paris France

## Published online: 01 September 2021

## Reference

 Badio, et al. Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries. Trials. 2021;22:86. https://doi.org/10.1186/s13 063-021-05035-9.



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

<sup>\*</sup> Correspondence: yazdan.yazdanpanah@aphp.fr

<sup>&</sup>lt;sup>†</sup>Moses Badio and Edouard Lhomme contributed equally to this work. <sup>9</sup>REACTing, Institut Thématique Immunologie, Inflammation, Infectiologie et Microbiologie, Inserm, Paris, France

<sup>&</sup>lt;sup>12</sup>AP-HP, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales, F-75018 Paris, France